DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will
report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the
U.S. financial markets. Company management will host a live audio
webcast at 4:30 p.m. ET /
9:30 p.m. IST to discuss 2024 first
quarter financial results and provide a business and financial
update.
Audio webcast/conference call:
U.S. Dial-In
Number: +1 800 715 9871
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 8991966
Interested parties may access the live audio webcast via the
Investors section of the Jazz Pharmaceuticals website at
https://investor.jazzpharma.com/investors/events-presentations. To
ensure a timely connection, it is recommended that participants
register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors
section of the Jazz Pharmaceuticals website at
https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals
plc (Nasdaq: JAZZ) is a global biopharma company whose purpose
is to innovate to transform the lives of patients and their
families. We are dedicated to developing life-changing medicines
for people with serious diseases — often with limited or no
therapeutic options. We have a diverse portfolio of marketed
medicines, including leading therapies for sleep disorders and
epilepsy, and a growing portfolio of cancer treatments. Our
patient-focused and science-driven approach powers pioneering
research and development advancements across our robust pipeline of
innovative therapeutics in oncology and neuroscience. Jazz is
headquartered in Dublin, Ireland with research and
development laboratories, manufacturing facilities and employees in
multiple countries committed to serving patients worldwide. Please
visit www.jazzpharmaceuticals.com for more
information.
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media Contact:
Kristin
Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Logo -
https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-report-2024-first-quarter-financial-results-on-may-1-2024-302120012.html